DE69232859T2 - Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden - Google Patents

Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Info

Publication number
DE69232859T2
DE69232859T2 DE69232859T DE69232859T DE69232859T2 DE 69232859 T2 DE69232859 T2 DE 69232859T2 DE 69232859 T DE69232859 T DE 69232859T DE 69232859 T DE69232859 T DE 69232859T DE 69232859 T2 DE69232859 T2 DE 69232859T2
Authority
DE
Germany
Prior art keywords
composition
virus polypeptides
several immune
immune reactive
reactive hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232859T
Other languages
English (en)
Other versions
DE69232859D1 (de
Inventor
J Weiner
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232859(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DE69232859D1 publication Critical patent/DE69232859D1/de
Application granted granted Critical
Publication of DE69232859T2 publication Critical patent/DE69232859T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69232859T 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden Expired - Lifetime DE69232859T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (2)

Publication Number Publication Date
DE69232859D1 DE69232859D1 (de) 2003-01-16
DE69232859T2 true DE69232859T2 (de) 2003-04-10

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232859T Expired - Lifetime DE69232859T2 (de) 1991-09-13 1992-09-11 Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Country Status (16)

Country Link
US (6) US5756312A (de)
EP (1) EP0608261B1 (de)
JP (5) JPH06511149A (de)
AT (1) ATE228564T1 (de)
AU (1) AU679429B2 (de)
BG (1) BG62973B1 (de)
CA (1) CA2116764C (de)
DE (1) DE69232859T2 (de)
DK (1) DK0608261T3 (de)
ES (1) ES2182822T3 (de)
FI (1) FI112438B (de)
HU (1) HU227510B1 (de)
PL (2) PL171972B1 (de)
RO (1) RO116199B1 (de)
RU (2) RU2212899C2 (de)
WO (1) WO1993006126A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
JPH06511149A (ja) * 1991-09-13 1994-12-15 カイロン　コーポレイション 免疫反応性ｃ型肝炎ウイルスのポリペプチド組成物
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
DE69332485T2 (de) * 1992-08-11 2003-11-13 Harvard College Immunmodulierende peptide
US6762024B2 (en) * 1993-04-27 2004-07-13 Innogenetics, S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP0697888B1 (de) 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DK0725824T3 (da) 1993-11-04 2003-08-11 Innogenetics Nv Immunodominante humane T-celleepitoper af hepatitis C virus
DE59511054D1 (de) 1994-07-25 2006-08-10 Roche Diagnostics Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
US6150134A (en) 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
EP1076092A3 (de) 1994-10-21 2001-03-28 Innogenetics N.V. Sequenzen von Hepatitis-C-Virus Typ 10, und dessen Verwendungen als vorbeugende. therapeutische und diagnostische Mitteln
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
WO1998021338A1 (en) 1996-11-08 1998-05-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
US6322965B1 (en) * 1997-02-10 2001-11-27 Advanced Life Science Institute, Inc. Chimera antigen peptide
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
AU752131C (en) * 1997-11-06 2003-12-04 Innogenetics N.V. Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US6689879B2 (en) 1998-12-31 2004-02-10 Chiron Corporation Modified HIV Env polypeptides
EP1141313A2 (de) 1998-12-31 2001-10-10 Chiron Corporation Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2000039304A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1535628B1 (de) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-ähnliche teilchen
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
IL153831A0 (en) * 2000-07-19 2003-07-31 Univ California Methods for therapy of neurodegenerative disease of the brain
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CA2419418A1 (en) 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6682909B2 (en) 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
JP4302513B2 (ja) * 2001-07-05 2009-07-29 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2005007808A2 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
US20050202036A1 (en) * 2003-07-22 2005-09-15 Branch Andrea D. Alternate reading frame polypeptides drived from hepatitis C and methods of their use
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
WO2006050394A2 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
WO2007031867A2 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-stru tural ns3/4a fusion gene
AU2007207544A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
US8071561B2 (en) * 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20100286070A1 (en) * 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
SG185263A1 (en) 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
WO2010117729A1 (en) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2453910B1 (de) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Einzeldosisformulierung von antidoten für faktor-xa-hemmer zur prävention von blutung
EP3424495A1 (de) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Öl-in-wasser-emulsionen mit nukleinsäuren
JP6120839B2 (ja) 2011-07-06 2017-04-26 ノバルティス アーゲー カチオン性水中油型エマルジョン
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
AU2013234046B2 (en) 2012-03-16 2017-09-07 University Health Network Methods and compositions for modulating Toso activity
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
CA2941697A1 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for modifying the immune response
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US20220275064A1 (en) 2019-07-08 2022-09-01 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
CN1074422C (zh) * 1987-11-18 2001-11-07 希龙股份有限公司 制备含有hcv表位的分离多肽的方法
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
MC2188A1 (fr) * 1989-05-18 1992-09-16 Chiron Corp Diagnostic du nanbv:polynucleotides permettant de depister le virus de l'hepatite c
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
DE59109221D1 (de) * 1990-11-03 2001-11-15 Dade Behring Marburg Gmbh HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
JPH06511149A (ja) * 1991-09-13 1994-12-15 カイロン　コーポレイション 免疫反応性ｃ型肝炎ウイルスのポリペプチド組成物

Also Published As

Publication number Publication date
AU2643692A (en) 1993-04-27
EP0608261A1 (de) 1994-08-03
DK0608261T3 (da) 2003-03-17
JP2002167336A (ja) 2002-06-11
FI941199A0 (fi) 1994-03-14
WO1993006126A1 (en) 1993-04-01
HU9400741D0 (en) 1994-06-28
RU2212899C2 (ru) 2003-09-27
JPH06511149A (ja) 1994-12-15
EP0608261A4 (de) 1995-03-15
JP2005176853A (ja) 2005-07-07
BG62973B1 (bg) 2000-12-29
HU227510B1 (en) 2011-07-28
PL171489B1 (pl) 1997-05-30
JP2004073207A (ja) 2004-03-11
US5728520A (en) 1998-03-17
RU2136311C1 (ru) 1999-09-10
BG98653A (bg) 1995-05-31
US5756312A (en) 1998-05-26
CA2116764C (en) 1999-12-07
ATE228564T1 (de) 2002-12-15
DE69232859D1 (de) 2003-01-16
FI112438B (fi) 2003-12-15
US5670152A (en) 1997-09-23
US6303292B1 (en) 2001-10-16
JP4353905B2 (ja) 2009-10-28
ES2182822T3 (es) 2003-03-16
US5670153A (en) 1997-09-23
EP0608261B1 (de) 2002-11-27
PL171972B1 (pl) 1997-07-31
CA2116764A1 (en) 1993-04-01
JP2008133301A (ja) 2008-06-12
RO116199B1 (ro) 2000-11-30
AU679429B2 (en) 1997-07-03
HUT67342A (en) 1995-03-28
FI941199A (fi) 1994-04-27
US5766845A (en) 1998-06-16

Similar Documents

Publication Publication Date Title
DE69232859D1 (de) Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
HUT73098A (en) Hepatitis c virus (hcv) polypeptides
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
EE200100292A (et) Peptiidligandidega kinnituvate mitmeste immunogeensete komponentidega HBV tuuma antigeensed osakesed
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
ATE64601T1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
IL128826A0 (en) A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide
IL134982A0 (en) Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
FR2676068B1 (fr) Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
FR2550203B1 (fr) Peptides synthetiques immunogenes porteurs d'un epitope caracteristique de l'antigene de surface du virus de l'hepatite b et compositions les contenant
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
PL273721A1 (en) Method of obtaining a polypeptide exhibiting antigenic properties in respect to the pre s1 region of hepatitis virus a areole
FR2556971B2 (fr) Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant
FR2549725B2 (fr) Fractions polypeptidiques inductrices d'anticorps protecteurs contre des parasites du paludisme et compositions immunogenes les contenant

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

R071 Expiry of right

Ref document number: 608261

Country of ref document: EP